Imugene share price surges 8% on 'crucial step forward' in US

Imugene is working on products intended to selectively kill tumour cells and activate the immune system against cancer cells.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imugene Ltd (ASX: IMU) share price is leaping higher today, up 7.5% at the time of writing.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotechnology company closed yesterday trading for 9.3 cents. Shares are currently swapping hands for 10 cents apiece.

Created with Highcharts 11.4.3Imugene PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Here's why ASX 200 investors are hitting the buy button today.

What did the ASX 200 biotech stock report?

The Imugene share price is racing higher after the company reported it had received a core patent from the United States Patent and Trademark Office.

The patent protects its oncolytic virotherapy CF33 products, including VAXINIA and CHECKVacc.

Imugene said both the method of composition and method of use of its licensed oncolytic virotherapy will be protected under the US patent until 2037.

According to the release, CF33 is a chimeric vaccinia poxvirus from the lab of inventor professor Yuman Fong. Oncolytic viruses are designed to selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.

Commenting on the patent grant sending the Imugene share price sharply higher today, CEO Leslie Chong said, "Imugene receiving this patent allowance for the CF33 family of oncolytic viruses from the US patent office is a crucial step forward."

She noted that the US is the biggest healthcare market on Earth, making "this is a particularly important patent milestone".

Imugene share price snapshot

Despite today's big intraday lift, the Imugene share price remains down a painful 62% over the past 12 months.

Investors who bought shares five years ago, however, will be sitting on gains of 400%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »